KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for TherapeuticsMD (TXMD) over the last 14 years, with Q3 2025 value amounting to $2.0 million.

  • TherapeuticsMD's Accumulated Expenses changed N/A to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year change of. This contributed to the annual value of $2.1 million for FY2024, which is 3210.98% down from last year.
  • TherapeuticsMD's Accumulated Expenses amounted to $2.0 million in Q3 2025.
  • TherapeuticsMD's Accumulated Expenses' 5-year high stood at $51.7 million during Q3 2021, with a 5-year trough of $1.6 million in Q2 2025.
  • Its 4-year average for Accumulated Expenses is $22.6 million, with a median of $3.1 million in 2023.
  • In the last 5 years, TherapeuticsMD's Accumulated Expenses surged by 107930.62% in 2021 and then tumbled by 3210.98% in 2024.
  • Over the past 4 years, TherapeuticsMD's Accumulated Expenses (Quarter) stood at $44.3 million in 2021, then plummeted by 92.93% to $3.1 million in 2023, then crashed by 32.11% to $2.1 million in 2024, then dropped by 5.27% to $2.0 million in 2025.
  • Its Accumulated Expenses was $2.0 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.8 million in Q1 2025.